Loading

Please wait...

Olumiant

Generic Name: baricitinib (BAR i SYE ti nib)
Brand Names: Olumiant
Olumiant (baricitinib) is used to reduce pain and stiffness in patients with rheumatoid arthritis. Includes Olumiant side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Olumiant

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Olumiant (baricitinib) blocks the activity of certain enzymes involved in activating inflammation in the body. Olumiant is used to reduce pain, stiffness, and swelling in adults with rheumatoid arthritis after other treatments have failed. Olumiant also helps slow the progression of bone and joint damage. Olumiant affects your immune system. You may get infections more easily, even serious or fatal infections. Call your doctor if you have a fever, chills, aches, tiredness, cough, skin sores, diarrhea, weight loss, or burning when you urinate. Learn more

Olumiant Side Effects

Olumiant Side Effects

Note: This document contains side effect information about baricitinib. Some of the dosage forms listed on this page may not apply to the brand name Olumiant.

For the Consumer

Applies to baricitinib: oral tablets

Warning

    Serious Infections
  • Serious, sometimes fatal infections including tuberculosis (pulmonary or extrapulmonary disease), bacterial and viral infections, invasive fungal infections (may be disseminated), and other opportunistic infections reported. (See Infectious Complications under Cautions.)

  • Carefully consider risks and benefits prior to initiating baricitinib therapy in patients with chronic or recurring infections.

  • Evaluate patients for latent tuberculosis infection prior to and periodically during treatment; if indicated, initiate appropriate antimycobacterial regimen prior to initiating baricitinib therapy.

  • Closely monitor patients for infection, including active tuberculosis in those with a negative test for latent tuberculosis, during and after treatment. If serious infection develops, interrupt baricitinib therapy until infection is controlled.

    Malignancies
  • Lymphoma and other malignancies reported. (See Malignancies and Lymphoproliferative Disorders under Cautions.)

    Thrombosis
  • Serious, sometimes fatal thromboembolic events, including DVT, PE, and arterial thrombosis, reported. Promptly evaluate patients with symptoms of thrombosis. (See Thromboembolic Events under Cautions.)

Side effects include:

Upper respiratory tract infection, nausea, herpes simplex, herpes zoster.

For Healthcare Professionals

Applies to baricitinib: oral tablet

Hematologic

Common (1% to 10%): Thrombocytosis, anemia

Uncommon (0.1% to 1%): Neutropenia

Frequency not reported: Lymphocytosis (occurs at higher rates in the elderly)

Immunologic

Common (1% to 10%): Herpes zoster, herpes simplex (e.g., eczema herpeticum, herpes simplex, ophthalmic herpes simplex, oral herpes), influenza

Musculoskeletal

Common (1% to 10%): Arthralgia, rheumatoid arthritis, back pain, muscle spasm, myalgia

Ocular

Common (1% to 10%): Blurred vision

Uncommon (0.1% to 1%): Cataract

Metabolic

Very common (10% or more): Hypercholesterolemia (34%)

Uncommon (0.1% to 1%): Hypertriglyceridemia, weight gain, creatine phosphokinase increased to greater than 5 times the upper limit of normal (ULN)

Psychiatric

Uncommon (0.1% to 1%): Insomnia, depression

Genitourinary

Common (1% to 10%): Urinary tract infection, benign prostatic hyperplasia

Uncommon (0.1% to 1%): Cystitis, erectile dysfunction, vulvovaginal candidiasis

Hepatic

Common (1% to 10%): ALT increased greater than or equal to 3 times the upper limit of normal (ULN)

Uncommon (0.1% to 1%): AST increased greater than or equal to 3 times the upper limit of normal (ULN), abnormal hepatic function

Respiratory

Very common (10% or more): Upper respiratory tract infections (e.g., sinusitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, tonsillitis, tracheitis) (15%)

Common (1% to 10%): Bronchitis, sinusitis, rhinitis, cough

Uncommon (0.1% to 1%): Tonsillitis

Other

Common (1% to 10%): Fatigue, pyrexia, peripheral edema

Nervous system

Common (1% to 10%): Headache, dizziness

Cardiovascular

Common (1% to 10%): Hypertension, coronary artery disease

Dermatologic

Uncommon (0.1% to 1%): Acne, alopecia, rash

Gastrointestinal

Common (1% to 10%): Nausea, gastroenteritis, dyspepsia, upper abdominal pain, constipation, vomiting, oropharyngeal pain, stomatitis, abdominal discomfort, gastroesophageal reflux disease

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Olumiant